In this issue:
- Intensification of ADT for biochemically recurrent prostate cancer
- Time to radical cystectomy and oncological outcomes
- Sacituzumab govitecan for metastatic urothelial carcinoma
- Enfortumab vedotin + pembrolizumab for untreated advanced urothelial cancer
- Nivolumab + cabozantinib for advanced RCC
- OS with adjuvant pembrolizumab in RCC
- Lenvatinib + pembrolizumab for advanced RCC
- Predictors of neoadjuvant chemotherapy response for MIBC
- Metastatic prostate cancer survival according to visceral metastatic location
- Neoadjuvant chemoradiotherapy and radical cystectomy for MIBC
- Adherence to AS in stage 1 testicular germ cell tumours
Please login below to download this issue (PDF)